\-\ Texto\\:\\ \ \(0\)\
\-\ \\â\\€\\¢\\ decreased\\ color\\ perception\\ on\\ right\\.\ \(0\)\
\-\ \\â\\€\\¢\\ no\\ proptosis\\ or\\ chemosis\ \(0\)\
\-\ high\\ dose\\ steroid\\ treatment\\.\ \(0\)\
\-\ \\â\\€\\¢\\ hyperintense\\ optic\\ nerve\\ on\\ right\\ on\\ t2\\ sequences\\.\ \(0\)\
\-\ \\â\\€\\¢\\ focal\\ enhancement\\ posterior\\ intra\\-orbital\\ portion\\ of\\ right\\ optic\\ nerve\\.\ \(0\)\
\-\ \\â\\€\\¢\\ normal\\ left\\ optic\\ nerve\\.\ \(0\)\
\-\ \\â\\€\\¢\\ hyperintense\\ lesion\\ in\\ cervical\\ cord\\ seen\\ on\\ gradient\\ echo\\ sagittal\\ study\\.\ \(0\)\
\-\ \\â\\€\\¢\\ neg\\ brain\\ mri\\.\ \(0\)\
\-\ devic\\ disease\\ \\(optic\\ neuritis\\ \\&\\ spinal\\ cord\\ plaques\\)\ \(0\)\
\-\ \\â\\€\\¢\\ optic\\ glioma\ \(0\)\
\-\ \\â\\€\\¢\\ sarcoidosis\ \(1\)\
\-\ \\â\\€\\¢\\ neuromyelitis\\ optica\\ \\(devic\\ disease\\)\ \(0\)\
\-\ \\â\\€\\¢\\ lyme\\ disease\ \(0\)\
\-\ 28\\ year\\ old\\ woman\\ presents\\ with\\ first\\ episode\\ of\\ right\\ eye\\ pain\\ and\\ decreased\\ vision\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ optic\\:\\ 0\\.1920245640584867\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.16735104725781325\ \(0\)\
\-\ devic\\:\\ 0\\.13992389342781353\ \(0\)\
\-\ nerve\\:\\ 0\\.08967804251904775\ \(0\)\
\-\ intra\\-orbital\\:\\ 0\\.07885797323695681\ \(0\)\
\-\ neuromyelitis\\:\\ 0\\.06996194671390676\ \(0\)\
\-\ optica\\:\\ 0\\.06996194671390676\ \(0\)\
\-\ hyperintense\\:\\ 0\\.06888660708549844\ \(0\)\
\-\ cord\\:\\ 0\\.0630519207806874\ \(0\)\
\-\ perception\\:\\ 0\\.06230702088512745\ \(0\)\
\-\ chemosis\\:\\ 0\\.06230702088512745\ \(0\)\
\-\ neuritis\\:\\ 0\\.05256622371169264\ \(0\)\
\-\ lyme\\:\\ 0\\.05135104756650812\ \(0\)\
\-\ neg\\:\\ 0\\.05079611150980959\ \(0\)\
\-\ gradient\\:\\ 0\\.0502711870314574\ \(0\)\
\-\ decreased\\:\\ 0\\.049335075781059404\ \(0\)\
\-\ proptosis\\:\\ 0\\.04633463258380532\ \(0\)\
\-\ plaques\\:\\ 0\\.04633463258380532\ \(0\)\
\-\ steroid\\:\\ 0\\.043800517774391534\ \(0\)\
\-\ dose\\:\\ 0\\.043414689340901105\ \(0\)\
\-\ echo\\:\\ 0\\.04316573370387841\ \(0\)\
\-\ episode\\:\\ 0\\.041073310148504134\ \(0\)\
\-\ disease\\:\\ 0\\.04068167595773896\ \(0\)\
\-\ color\\:\\ 0\\.040496383736166264\ \(0\)\
\-\ 28\\:\\ 0\\.0391070551571306\ \(0\)\
\-\ vision\\:\\ 0\\.038329941490397236\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.03747273171228386\ \(0\)\
\-\ glioma\\:\\ 0\\.037404599938898934\ \(0\)\
\-\ right\\:\\ 0\\.03501482365477346\ \(0\)\
\-\ eye\\:\\ 0\\.03480009521467875\ \(0\)\
\-\ sequences\\:\\ 0\\.03464557623112633\ \(0\)\
\-\ sagittal\\:\\ 0\\.03309074419909106\ \(0\)\
\-\ cervical\\:\\ 0\\.030146518510598335\ \(0\)\
\-\ portion\\:\\ 0\\.03005054997436006\ \(0\)\
\-\ spinal\\:\\ 0\\.029706565149316366\ \(0\)\
\-\ \\&\\:\\ 0\\.029139688273217782\ \(0\)\
\-\ on\\:\\ 0\\.028112272324870992\ \(0\)\
\-\ first\\:\\ 0\\.027839644997920892\ \(0\)\
\-\ study\\:\\ 0\\.027297391814174357\ \(0\)\
\-\ brain\\:\\ 0\\.024964577896143317\ \(0\)\
\-\ focal\\:\\ 0\\.02369411266153788\ \(0\)\
\-\ t2\\:\\ 0\\.02348144435679953\ \(0\)\
\-\ high\\:\\ 0\\.02270433069006617\ \(0\)\
\-\ enhancement\\:\\ 0\\.02223775501090326\ \(0\)\
\-\ woman\\:\\ 0\\.01916410628630006\ \(0\)\
\-\ posterior\\:\\ 0\\.019122704356334452\ \(0\)\
\-\ mri\\:\\ 0\\.019060930630239028\ \(0\)\
\-\ presents\\:\\ 0\\.016948002869008987\ \(0\)\
\-\ lesion\\:\\ 0\\.016898594427188877\ \(0\)\
\-\ treatment\\:\\ 0\\.01679239766602803\ \(0\)\
\-\ seen\\:\\ 0\\.016394442864734855\ \(0\)\
\-\ \\(\\:\\ 0\\.014026441286288552\ \(0\)\
\-\ \\)\\:\\ 0\\.013855100817734079\ \(0\)\
\-\ normal\\:\\ 0\\.01300594616115632\ \(0\)\
\-\ pain\\:\\ 0\\.010132118131366356\ \(0\)\
\-\ or\\:\\ 0\\.0097235218345991\ \(0\)\
\-\ left\\:\\ 0\\.009282575429834123\ \(0\)\
\-\ year\\:\\ 0\\.009282575429834123\ \(0\)\
\-\ old\\:\\ 0\\.008494510649148102\ \(0\)\
\-\ no\\:\\ 0\\.008353826705862155\ \(0\)\
\-\ in\\:\\ 0\\.0040912352440801445\ \(0\)\
\-\ \\.\\:\\ 0\\.0027572455221239823\ \(0\)\
\-\ of\\:\\ 0\\.0022622097242327847\ \(0\)\
\-\ and\\:\\ 0\\.0017476602498273635\ \(0\)\
\-\ with\\:\\ 0\\.0011359628746591235\ \(0\)\
